A novel monoclonal antibody to fibroblast growth factor 2 effectively inhibits growth of hepatocellular carcinoma xenografts

Molecular Cancer Therapeutics

Volumn 11, Issue 4, 2012, Pages 864-872

  Wang, Lihong ^a   Park, Hangil ^a   Chhim, Sophea ^a   Ding, Yi ^a   Jiang, Wei ^a   Queen, Cary ^a   Kim, K Jin ^a  

^a Galaxy Biotech LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 2; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY A.4.6.1; MONOCLONAL ANTIBODY GAL F2; SORAFENIB; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; LIVER CELL CARCINOMA; MALE; NONHUMAN; PRIORITY JOURNAL; UMBILICAL VEIN ENDOTHELIAL CELL; WESTERN BLOTTING;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; CARCINOMA, HEPATOCELLULAR; CELL GROWTH PROCESSES; CELL LINE, TUMOR; FEMALE; FIBROBLAST GROWTH FACTOR 2; HUMANS; LIVER NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; MOLECULAR SEQUENCE DATA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84862751803     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-11-0813     Document Type: Article

References (41)

1. Ornitz DM, Itoh N. Fibroblast growth factors. Genome Biol 2001;2:REVIEWS3005.
2. Presta M, Dell'Era P, Mitola S, Moroni E, Ronca R, Rusnati M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 2005;16:159-78. (Pubitemid 40616114)
3. Okada-Ban M, Thiery JP, Jouanneau J. Fibroblast growth factor-2. Int J Biochem Cell Biol 2000;32:263-7. (Pubitemid 30069969)
4. Mignatti P, Morimoto T, Rifkin DB. Basic fibroblast growth factor, a protein devoid of secretory signal sequence, is released by cells via a pathway independent of the endoplasmic reticulum-Golgi complex. J Cell Physiol 1992;151:81-93.
5. Ornitz DM, Xu J, Colvin JS, McEwenDG, MacArthur CA, Coulier F, et al. Receptor specificity of the fibroblast growth factor family. J Biol Chem 1996;271:15292-97. (Pubitemid 26195013)
6. Mohammadi M, Olsen SK, Ibrahimi OA. Structural basis for fibroblast growth factor receptor activation. Cytokine Growth Factor Rev 2005;16:107-37. (Pubitemid 40616111)
7. Dow JK, deVere White RW. Fibroblast growth factor 2: its structure and property, paracrine function, tumor angiogenesis, and prostate-related mitogenic and oncogenic functions. Urology 2000;55:800-06. (Pubitemid 30330774)
8. Takahashi JA, Mori H, Fukumoto M, Igarashi K, Jaye M, Oda Y, et al. Gene expression of fibroblast growth factors in human gliomas and meningiomas: demonstration of cellular source of basic fibroblast growth factor mRNA and peptide in tumor tissues. Proc Natl Acad Sci USA 1990;87:5710-14.
9. Wang Y, Becker D. Antisense targeting of basic fibroblast growth factor and fibroblast growth factor receptor-1 in human melanomas blocks intratumoral angiogenesis and tumor growth. Nat Med 1997;3:887-93. (Pubitemid 27353449)
10. Yamanaka Y, Friess H, Buchler M, Beger HG, Uchida E, Onda M, et al. Overexpression of acidic and basic fibroblast growth factors in human pancreatic cancer correlates with advanced tumor stage. Cancer Res 1993;53:5289-96. (Pubitemid 23333401)
11. Barclay C, Li AW, Geldenhuys L, Baguma-Nibasheka M, Porter GA, Veugelers PJ, et al. Basic fibroblast growth factor (FGF2) overexpression is a risk factor for esophageal cancer recurrence and reduced survival, which is ameliorated by coexpression of the FGF2 antisense gene. Clin Cancer Res 2005;11:7683-91. (Pubitemid 41611610)
12. Boelaert K, McCabe CJ, Tannahill LA, Gittoes NJ, Holder RL, Watkinson JC, et al. Pituitary tumor transforming gene and fibroblast growth factor-2 expression: potential prognostic indicators in differentiated thyroid cancer. J Clin Endocrinol Metab 2003;88:2341-47. (Pubitemid 36549916)
13. Finn RS. Development of molecularly targeted therapies in hepatocellular carcinoma: where do we go now? Clin Cancer Res 2010;16:390-7.
14. Ribatti D, Vacca A, Nico B, Sansonno D, Dammacco F. Angiogenesis and anti-angiogenesis in hepatocellular carcinoma. Cancer Treatment Rev 2006;32:437-44. (Pubitemid 44309250)
15. Poon RT, Ng IO, Lau C, Yu WC, Fan ST, Wong J. Correlation of serum basic fibroblast growth factor levels with clinicopathologic features and postoperative recurrence in hepatocellular carcinoma. Am J Surg 2001;182:298-304. (Pubitemid 32918381)
16. Kin M, Sata M, Ueno T, Torimura T, Inuzuka S, Tsuji R, et al. Basic fibroblast growth factor regulates proliferation and motility of human hepatoma cells by an autocrine mechanism. J Hepatol 1997;27:677-87. (Pubitemid 27448752)
17. Asada N, Tanaka Y, Hayashido Y, Toratani S, Kan M, Kitamoto M, et al. Expression of fibroblast growth factor receptor genes in human hepatoma-derived cell lines. In Vitro Cell Dev Biol Anim 2003;39:321-328. (Pubitemid 38200255)
18. Ogasawara S, Yano H, Iemura A, Hisaka T, Kojiro M. Expressions of basic fibroblast growth factor and its receptors and their relationship to proliferation of human hepatocellular carcinoma cell lines. Hepatology 1996;24:198-205. (Pubitemid 26249434)
19. Maret A, Galy B, Arnaud E, Bayard F, Prats H. Inhibition of fibroblast growth factor 2 expression by antisense RNA induced a loss of the transformed phenotype in a human hepatoma cell line. Cancer Res 1995;55:5075-79.
20. Reilly TM, Taylor DS, Herblin WF, Thoolen MJ, Chiu AT, Watson DW, et al. Monoclonal antibodies directed against basic fibroblast growth factor which inhibit its biological activity in vitro and in vivo. Biochem Biophys Res Commun 1989;164:736-43. (Pubitemid 19280330)
21. Matsuzaki K, Yoshitake Y, Matuo Y, Sasaki H, Nishikawa K. Monoclonal antibodies against heparin-binding growth factor II/basic fibroblast growth factor that block its biological activity: invalidity of the antibodies for tumor angiogenesis. Proc Natl Acad Sci USA 1989;86:9911-15. (Pubitemid 20030744)
22. Aonuma M, Yoshitake Y, Nishikawa K, Tanaka NG. Different antitumor activities of anti-bFGF neutralizing antibodies: heparin-binding domain provides an inefficient epitope for neutralization in vivo. Anticancer Res 1999;19:4039-44.
23. Rege AA, Bjercke RJ, Erichsen D, Owens R, Stephan CC, Brock TA. Development of novel monoclonal antibodies for the analysis of functional sites in FGF-2. Growth Factors 1999;16:161-9. (Pubitemid 129725721)
24. Kuhn H, Köpff C, Konrad J, Riedel A, Gessner C, Wirtz H. Influence of basic fibroblast growth factor on the proliferation of non-small cell lung cancer cell lines. Lung Cancer 2004;44:167-74. (Pubitemid 38482049)
25. Hori A, Sasada R, Matsutani E, Naito K, Sakura Y, Fujita T, et al. Suppression of solid tumor growth by immunoneutralizing monoclonal antibody against human basic fibroblast growth factor. Cancer Res 1991;51:6180-4.
26. Takahashi JA, Fukumoto M, Kozai Y, Ito N, Oda Y, Kikuchi H, et al. Inhibition of cell growth and tumorigenesis ofhuman glioblastoma cells by a neutralizing antibody against human basic fibroblast growth factor. FEBS Lett 1991;288:65-71.
27. Chuntharapai A, Kim KJ. Generation of monoclonal antibodies to chemokine receptors. Methods Enzymol 1997;288:15-27.
28. Ibrahimi OA, Eliseenkova AV, Plotnikov AN, Yu K, Ornitz DM, Mohammadi M. Structural basis for fibroblast growth factor receptor 2 activation in Apert syndrome. Proc Natl Acad Sci USA 2001;98:7182-7.
29. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993;362:841-4. (Pubitemid 23132159)
30. Heffelfinger SC, Hawkins HH, Barrish J, Taylor L, Darlington GJ. SK HEP-1: a human cell line of endothelial origin. In Vitro Cell Dev Biol 1992;28A:136-42.
31. American Cancer Society. Cancer facts and figures 2009. Atlanta, GA: American Cancer Society; 2009.
32. Garcia M, Jemal A, Ward EM, CenterMM,Hao Y, Siegel RL, et al.Global cancer facts & figures 2007. Atlanta, GA: American Cancer Society;2007.
33. Huynh H. Molecularly targeted therapy in hepatocellular carcinoma. Biochem Pharmacol 2010;80:550-60.
34. Huynh H, Ngo VC, Fargnoli J, Ayers M, Soo KC, Koong HN, et al. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. Clin Cancer Res 2008;14:6146-53.
35. Pfizer discontinues phase 3 trial of Sutent in advanced hepatocellular carcinoma. New York, NY: Pfizer; Apr 22, 2010.
36. Thomas MB, Morris JS, Chadha R, Iwasaki M, Kaur H, Lin E, et al. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol 2009;27:843-50.
37. Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Hicklin DJ, et al. Synergistic effect of basic fibroblast growth factor and vascular endothelial growth factor in murine hepatocellular carcinoma. Hepatology 2002;35:834-42. (Pubitemid 34258377)
38. Dempke WC, Heinemann V. Resistance to EGF-R (erbB-1) and VEGFR modulating agents. Eur J Cancer 2009;45:1117-28.
39. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005;8:299-309. (Pubitemid 41443415)
40. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008;8:592-603.
41. Gospodarowicz D. Purification of a fibroblast growth factor from bovine pituitary. J Biol Chem 1975;250:2515-20.